RKI-1447 significantly reduced engraftment compared to the control (DMSO-treated) group and inhibited both myeloid and multi-lineage engraftment of SRSF2-mutated AML samples (Figure S3B, Data S8), while RKI-1447 had no significant effect on SRSF2 WT primary AML samples (Figure S3C, Data S8). This evidence concerns the gene SRSF2 and acute myeloid leukemia.